RSS-Feed abonnieren

DOI: 10.1055/s-0042-1748947
Efficacy of Ibuprofen after Total Hip Arthroplasty to Prevent Heterotopic Ossification: Systematic Review and Meta-Analysis[*]
Artikel in mehreren Sprachen: português | EnglishFinancial Support No grant or other financial support has been received for conducting this study.

Abstract
The objective of this study was to conduct a systematic review and meta-analysis of relevant randomized control trials (RCTs) to determine the role of ibuprofen, as well as the optimum dose and duration of therapy, in preventing the incidence of heterotopic ossification (HO) after primary total hip arthroplasty (THA). A literature search was performed using the PubMed/MEDLINE and Cochrane Library databases for RCTs that compared the use of ibuprofen versus placebo as prophylaxis for HO in patients after THA. The main outcomes for this study were overall occurrence of HO, occurrence according to the Brooker classification, and gastrointestinal complications. A total of 27 potential articles were identified from the database. Eventually, four trials with 1,153 patients were included in the final analysis. When compared with placebo, the use of ibuprofen is associated with a reduction in the incidence of HO at the 3- and 12-month follow-up appointments, as well as the incidence of Brooker II and III HO (p < 0.05). However, there was no significant difference between the ibuprofen and placebo groups in terms of treatment discontinuation due to gastrointestinal complications or the incidence of Brooker I and IV HO (p > 0.05). The existing data indicates that ibuprofen is safe and efficacious in reducing the total incidence of HO along with Brooker II and III HO at follow-up. However, due to the small number of studies, the conclusions are limited; therefore, more high-quality clinical trials are required to develop guidelines for optimal dose and duration of therapy.
* Work developed at Department of Orthopaedic Surgery, Dow International Medical College, Karachi, Pakistan
Publikationsverlauf
Eingereicht: 01. September 2021
Angenommen: 14. März 2022
Artikel online veröffentlicht:
27. Juni 2022
© 2022. Sociedade Brasileira de Ortopedia e Traumatologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
Referências
- 1
Varacallo M,
Chakravarty R,
Denehy K,
Star A.
Joint perception and patient perceived satisfaction after total hip and knee arthroplasty
in the American population. J Orthop 2018; 15 (02) 495-499
MissingFormLabel
- 2
Hansson S,
Bülow E,
Garland A,
Kärrholm J,
Rogmark C.
More hip complications after total hip arthroplasty than after hemi-arthroplasty as
hip fracture treatment: analysis of 5,815 matched pairs in the Swedish Hip Arthroplasty
Register. Acta Orthop 2020; 91 (02) 133-138
MissingFormLabel
- 3
Healy WL,
Iorio R,
Clair AJ,
Pellegrini VD,
Della Valle CJ,
Berend KR.
Complications of Total Hip Arthroplasty: Standardized List, Definitions, and Stratification
Developed by The Hip Society. Clin Orthop Relat Res 2016; 474 (02) 357-364
MissingFormLabel
- 4
Rosteius T,
Rausch V,
Pätzholz S.
et al.
Incidence and risk factors for heterotopic ossification following periprosthetic joint
infection of the hip. Arch Orthop Trauma Surg 2019; 139 (09) 1307-1314
MissingFormLabel
- 5
Brooker AF,
Bowerman JW,
Robinson RA,
Riley Jr LHJ.
Ectopic ossification following total hip replacement. Incidence and a method of classification.
J Bone Joint Surg Am 1973; 55 (08) 1629-1632
MissingFormLabel
- 6
Zhu Y,
Zhang F,
Chen W,
Zhang Q,
Liu S,
Zhang Y.
Incidence and risk factors for heterotopic ossification after total hip arthroplasty:
a meta-analysis. Arch Orthop Trauma Surg 2015; 135 (09) 1307-1314
MissingFormLabel
- 7
Manrique J,
Alijanipour P,
Heller S,
Dove M,
Parvizi J.
Increased Risk of Heterotopic Ossification Following Revision Hip Arthroplasty for
Periprosthetic Joint Infection. Arch Bone Jt Surg 2018; 6 (06) 486-491
MissingFormLabel
- 8
Eggli S,
Woo A.
Risk factors for heterotopic ossification in total hip arthroplasty. Arch Orthop Trauma
Surg 2001; 121 (09) 531-535
MissingFormLabel
- 9
Rüdiger HA,
Dittrich M,
Robinson J.
et al.
The Impact of Heterotopic Ossification on Self-Reported Outcomes After Total Hip Arthroplasty
Using the Direct Anterior Approach. J Bone Joint Surg Am 2020; 102 (Suppl. 02) 91-98
MissingFormLabel
- 10
van Erp JHJ,
Massier JRA,
Truijen S,
Bekkers JEJ,
Snijders TE,
de Gast A.
Heterotopic ossification in primary total hip arthroplasty using the posterolateral
compared to the direct lateral approach. Arch Orthop Trauma Surg 2021; 141 (07) 1253-1259
MissingFormLabel
- 11
Shapira J,
Yelton MJ,
Chen JW.
et al.
Efficacy of NSAIDs versus radiotherapy for heterotopic ossification prophylaxis following
total hip arthroplasty in high-risk patients: a systematic review and meta-analysis.
Hip Int 2021; 1120700021991115
MissingFormLabel
- 12
Rosenberg DM,
Onderdonk B,
Majeed NK.
et al.
Radiation-Induced Sarcoma After Heterotopic Ossification Prophylaxis: A Case Report.
JBJS Case Connect 2019; 9 (04) e0146
MissingFormLabel
- 13
Strauss JB,
Chen SS,
Shah AP,
Coon AB,
Dickler A.
Cost of radiotherapy versus NSAID administration for prevention of heterotopic ossification
after total hip arthroplasty. Int J Radiat Oncol Biol Phys 2008; 71 (05) 1460-1464
MissingFormLabel
- 14
Kan SL,
Yang B,
Ning GZ.
et al.
Nonsteroidal Anti-inflammatory Drugs as Prophylaxis for Heterotopic Ossification after
Total Hip Arthroplasty: A Systematic Review and Meta-Analysis. Medicine (Baltimore)
2015; 94 (18) e828
MissingFormLabel
- 15
Moher D,
Liberati A,
Tetzlaff J,
Altman DG.
PRISMA Group.
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
BMJ 2009; 339: b2535
MissingFormLabel
- 16
Higgins JP,
Altman DG,
Gøtzsche PC.
et al;
Cochrane Bias Methods Group,
Cochrane Statistical Methods Group.
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.
BMJ 2011; 343: d5928
MissingFormLabel
- 17
DerSimonian R,
Laird N.
Meta-analysis in clinical trials. Control Clin Trials 1986; 7 (03) 177-188
MissingFormLabel
- 18
Higgins JPT,
Thompson SG,
Deeks JJ,
Altman DG.
Measuring inconsistency in meta-analyses. BMJ 2003; 327 (7414): 557-560
MissingFormLabel
- 19
Fransen M,
Anderson C,
Douglas J.
et al;
HIPAID Collaborative Group.
Safety and efficacy of routine postoperative ibuprofen for pain and disability related
to ectopic bone formation after hip replacement surgery (HIPAID): randomised controlled
trial. BMJ 2006; 333 (7567): 519
MissingFormLabel
- 20
Persson PE,
Sodemann B,
Nilsson OS.
Preventive effects of ibuprofen on periarticular heterotopic ossification after total
hip arthroplasty. A randomized double-blind prospective study of treatment time. Acta
Orthop Scand 1998; 69 (02) 111-115
MissingFormLabel
- 21
Ahrengart L,
Blomgren G,
Törnkvist H.
Short-term ibuprofen to prevent ossification after hip arthroplasty. No effects in
a prospective randomized study of 47 arthrosis cases. Acta Orthop Scand 1994; 65 (02)
139-141
MissingFormLabel
- 22
Elmstedt E,
Lindholm TS,
Nilsson OS,
Törnkvist H.
Effect of ibuprofen on heterotopic ossification after hip replacement. Acta Orthop
Scand 1985; 56 (01) 25-27
MissingFormLabel
- 23
Sterne JA,
Sutton AJ,
Ioannidis JP.
et al.
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses
of randomised controlled trials. BMJ 2011; 343: d4002
MissingFormLabel
- 24
Nauth A,
Giles E,
Potter BK.
et al.
Heterotopic ossification in orthopaedic trauma. J Orthop Trauma 2012; 26 (12) 684-688
MissingFormLabel
- 25
Meyers C,
Lisiecki J,
Miller S.
et al.
Heterotopic Ossification: A Comprehensive Review. JBMR Plus 2019; 3 (04) e10172
MissingFormLabel
- 26
Firoozabadi R,
Alton T,
Sagi HC.
Heterotopic Ossification in Acetabular Fracture Surgery. J Am Acad Orthop Surg 2017;
25 (02) 117-124
MissingFormLabel
- 27
Gebuhr P,
Soelberg M,
Orsnes T,
Wilbek H.
Naproxen prevention of heterotopic ossification after hip arthroplasty. A prospective
control study of 55 patients. Acta Orthop Scand 1991; 62 (03) 226-229
MissingFormLabel
- 28
Wahlström O,
Risto O,
Djerf K,
Hammerby S.
Heterotopic bone formation prevented by diclofenac. Prospective study of 100 hip arthroplasties.
Acta Orthop Scand 1991; 62 (05) 419-421
MissingFormLabel
- 29
Grohs JG,
Schmidt M,
Wanivenhaus A.
Selective COX-2 inhibitor versus indomethacin for the prevention of heterotopic ossification
after hip replacement: a double-blind randomized trial of 100 patients with 1-year
follow-up. Acta Orthop 2007; 78 (01) 95-98
MissingFormLabel
- 30
Legenstein R,
Bösch P,
Ungersböck A.
Indomethacin versus meloxicam for prevention of heterotopic ossification after total
hip arthroplasty. Arch Orthop Trauma Surg 2003; 123 (2-3): 91-94
MissingFormLabel
- 31
Sagi HC,
Jordan CJ,
Barei DP,
Serrano-Riera R,
Steverson B.
Indomethacin prophylaxis for heterotopic ossification after acetabular fracture surgery
increases the risk for nonunion of the posterior wall. J Orthop Trauma 2014; 28 (07)
377-383
MissingFormLabel
- 32
Zhu XT,
Chen L,
Lin JH.
Selective COX-2 inhibitor versus non-selective COX-2 inhibitor for the prevention
of heterotopic ossification after total hip arthroplasty: A meta-analysis. Medicine
(Baltimore) 2018; 97 (31) e11649
MissingFormLabel
- 33
Macfarlane RJ,
Ng BH,
Gamie Z.
et al.
Pharmacological treatment of heterotopic ossification following hip and acetabular
surgery. Expert Opin Pharmacother 2008; 9 (05) 767-786
MissingFormLabel
- 34
Walker C.
Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib,
and Diclofenac. Int J Rheumatol 2018; 2018: 1302835
MissingFormLabel
- 35
Sibbald B.
Rofecoxib (Vioxx) voluntarily withdrawn from market. CMAJ 2004; 171 (09) 1027-1028
MissingFormLabel
- 36
Solomon SD,
Wittes J,
Finn PV.
et al;
Cross Trial Safety Assessment Group.
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross
trial safety analysis. Circulation 2008; 117 (16) 2104-2113
MissingFormLabel
- 37
Hug KT,
Alton TB,
Gee AO.
Classifications in brief: Brooker classification of heterotopic ossification after
total hip arthroplasty. Clin Orthop Relat Res 2015; 473 (06) 2154-2157
MissingFormLabel
- 38
Mary Jiayi T,
Linda P,
Michael P.
et al.
Potential discrepancy between plain films and CT scans in Brooker classification of
heterotopic ossification. Br J Radiol 2017; 90 (1080): 20170263
MissingFormLabel
- 39
Nilsdotter A,
Bremander A.
Measures of hip function and symptoms: Harris Hip Score (HHS), Hip Disability and
Osteoarthritis Outcome Score (HOOS), Oxford Hip Score (OHS), Lequesne Index of Severity
for Osteoarthritis of the Hip (LISOH), and American Academy of Orthopedic Surgeons
(AAOS) Hip and Knee Questionnaire. Arthritis Care Res (Hoboken) 2011; 63 (Suppl. 11)
S200-S207
MissingFormLabel